Literature DB >> 8955970

Neostigmine but not edrophonium prolongs the action of mivacurium.

M J Symington1, R K Mirakhur, N Kumar.   

Abstract

PURPOSE: To examine the influence of anticholinesterase drugs neostigmine and edrophonium (which have different effects on plasma cholinesterase activity) administered for antagonism of neuromuscular block on the duration of action of mivacurium (a neuromuscular blocking drug metabolised by plasma cholinesterase).
METHODS: This was a randomized study where mivacurium 0.15 mg.kg-1 was administered to a control group or after administration of neostigmine 40 micrograms.kg-1 or edrophonium 1 mg.kg-1 (n = 10 for each group) administered 10 min earlier for antagonism of atracurium-induced neuromuscular block. Neuromuscular block was measured by stimulation of the ulnar nerve in a train-of-four mode (TOF) and measuring the force of contraction of the adductor pollicis muscle. Baseline plasma cholinesterase activity was estimated before drug administration in all the groups and following anticholinesterase administration.
RESULTS: The times to recovery of T1 (first response in the TOF) to 25 and 90% of control and of the TOF ratio to 0.7 after 0.15 mg.kg-1 of mivacurium were 47, 65 and 70 min in the neostigmine group; 25, 36 and 36 min in the edrophonium group and 17, 29 and 27 min respectively in the control group (P < 0.01). The plasma cholinesterase activity (PCHE) after neostigmine decreased from 6596 to 1959 U.L-1 (P < 0.001) but there was no change after edrophonium (6140 to 6396 U.L-1).
CONCLUSIONS: The duration of action of mivacurium is prolonged by previous administration of neostigmine and this is most likely to be due to inhibition of PCHE activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8955970     DOI: 10.1007/BF03013428

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  9 in total

1.  Investigation on the acetylcholinesterase activity of erythrocytes, platelets and plasma in different animal species.

Authors:  J ZAJICEK; N DATTA
Journal:  Acta Haematol       Date:  1953-02       Impact factor: 2.195

2.  The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). A short-acting nondepolarizing ester neuromuscular blocking drug.

Authors:  J J Savarese; H H Ali; S J Basta; P B Embree; R P Scott; N Sunder; J N Weakly; W B Wastila; H A el-Sayad
Journal:  Anesthesiology       Date:  1988-05       Impact factor: 7.892

3.  Comparison of the effects of neostigmine and edrophonium on the duration of action of suxamethonium.

Authors:  E P McCoy; R K Mirakhur
Journal:  Acta Anaesthesiol Scand       Date:  1995-08       Impact factor: 2.105

4.  Effects of cholinesterase inhibitors on the neuromuscular blocking action of suxamethonium.

Authors:  J B Valdrighi; N W Fleming; B K Smith; G L Baker; D A White
Journal:  Br J Anaesth       Date:  1994-02       Impact factor: 9.166

5.  Effects of neostigmine and pyridostigmine on serum cholinesterase activity.

Authors:  R K Mirakhur; T D Lavery; L P Briggs; R S Clarke
Journal:  Can Anaesth Soc J       Date:  1982-01

6.  Edrophonium and plasma cholinesterase activity.

Authors:  R K Mirakhur
Journal:  Can Anaesth Soc J       Date:  1986-09

7.  Protein binding of atracurium and other short-acting neuromuscular blocking agents and their interaction with human cholinesterases.

Authors:  F F Foldes; A Deery
Journal:  Br J Anaesth       Date:  1983       Impact factor: 9.166

8.  Cholinesterase inhibitors do not prolong neuromuscular block produced by mivacurium.

Authors:  N W Fleming; B K Lewis
Journal:  Br J Anaesth       Date:  1994-08       Impact factor: 9.166

9.  Influence of plasma cholinesterase activity on recovery from mivacurium-induced neuromuscular blockade in phenotypically normal patients.

Authors:  D Ostergaard; F S Jensen; E Jensen; L T Skovgaard; J Viby-Mogensen
Journal:  Acta Anaesthesiol Scand       Date:  1992-10       Impact factor: 2.105

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.